Holen Sie sich die Stockscreener-App
0.9119
10.51%
0.0867
Vorhandelsmarkt:
.99
0.0781
+8.56%
Schlusskurs vom Vortag:
$0.8252
Offen:
$0.8315
24-Stunden-Volumen:
321.31K
Relative Volume:
1.53
Marktkapitalisierung:
$81.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-1.0021
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
+36.08%
1M Leistung:
+57.99%
6M Leistung:
-9.71%
1J Leistung:
-55.30%
1-Tages-Spanne:
$0.8315
$0.95
1-Wochen-Bereich:
$0.666
$0.95
52-Wochen-Spanne:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Vergleichen Sie CNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.9119 | 60.11M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
How Bio Techne Corporation stock performs during market volatilityFree Expert-Led Investment Training - Newser
Why Context Therapeutics Inc. stock attracts strong analyst attentionShort Term High Return Strategy - Newser
How Context Therapeutics Inc. stock performs during market volatilityBig Return Stock Tips - Newser
Why VTGN stock attracts strong analyst attentionFree Stock Investment Growth Plan - Newser
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - GlobeNewswire
What makes HighPeak Energy Inc. stock price move sharplyBest Stocks for Capital Safety - Newser
What makes Five Point Holdings LLC stock price move sharplyFree High-Profit Stock Picks - Newser
What makes Humana Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
What makes Context Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - Newser
What makes Heritage Insurance Holdings Inc. stock price move sharplyFree Stock Market Courses - Newser
How Seneca Foods Corporation stock performs during market volatilityFree Investment Risk Control - Newser
How BlackSky Technology Inc. stock performs during market volatilityTargeted 200 Percent Gain - Newser
What makes EastGroup Properties Inc. stock price move sharplyFree Access to Stock Community - Newser
Why AREC stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Rare Stock Picks In June 2025From 26 Discerning Analysts - Seeking Alpha
Piper Sandler Remains a Buy on Context Therapeutics (CNTX) - The Globe and Mail
Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $6.00 - Defense World
Dominari (NASDAQ:DOMH) and Context Therapeutics (NASDAQ:CNTX) Critical Comparison - Defense World
Piper Sandler Adjusts Price Target for Context Therapeutics (CNT - GuruFocus
In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities - Yahoo Finance
Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Purchases 34,835 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Has $191,000 Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Context Therapeutics Approves Reverse Stock Split Amendment - TipRanks
Context Therapeutics Inc (CNTX) Stock: From Low to High in 52 Weeks - investchronicle.com
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MSN
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - simplywall.st
Insider Spends US$70k Buying More Shares In Context Therapeutics - 富途牛牛
Context Therapeutics Executives Increase Holdings - TradingView
Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha
Jane Street Group LLC Makes New $29,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
ContextLogic's OTC Gamble: Can a $6 Floor Launch a $15 Comeback? - AInvest
CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results - mx.advfn.com
Northern Trust Corp Sells 58,946 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire
Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus
Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire
Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan
Surging Prevalence Of Breast Cancer Fuels Expansion In The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drug... - WhaTech
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN
Unpacking Q1 Earnings: Privia Health (NASDAQ:PRVA) In The Context Of Other Healthcare Technology for Providers Stocks - Yahoo Finance
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):